Corpus ID: 2655642

Candesartan and progression of preglomerular lesions in N(G)-nitro-L-arginine methyl ester hypertensive rats.

@article{Casellas1999CandesartanAP,
  title={Candesartan and progression of preglomerular lesions in N(G)-nitro-L-arginine methyl ester hypertensive rats.},
  author={D. Casellas and S. Benahmed and A. Artuso and B. Jover},
  journal={Journal of the American Society of Nephrology : JASN},
  year={1999},
  volume={10 Suppl 11},
  pages={
          S230-3
        }
}
Chronic administration of N(G)-nitro-L-arginine methyl ester (L-NAME) to rats induces systemic hypertension and progressive development of preglomerular sudanophilic (SB+) lesions. This study investigates whether progression of SB+ lesion formation froin 4 to 6 wk of L-NAME treatment (20 mg/kg per d, orally) would be affected by 2 wk administration of either the angiotensin II type 1 receptor antagonist candesartan cilexetil (3 and 10 mg/kg per d) or the vasodilator hydralazine (15 mg/kg per d… Expand
Candesartan prevents L-NAME-induced cardio-renal injury in spontaneously hypertensive rats beyond hypotensive effects
Olmesartan improves endothelin-induced hypertension and oxidative stress in rats.
  • L. Yao, H. Kobori, +7 authors A. Nishiyama
  • Chemistry, Medicine
  • Hypertension research : official journal of the Japanese Society of Hypertension
  • 2004
Nitric Oxide Inhibition and Renal Alterations
Reduced nitric oxide bioavailability contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome.
  • J. Frisbee
  • Chemistry, Medicine
  • American journal of physiology. Regulatory, integrative and comparative physiology
  • 2005
...
1
2
...